- Home
- SVM vs STOK Comparison
SVM vs STOK Comparison
Compare SVM & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVM
- STOK
- Stock Information
- Founded
- SVM N/A
- STOK 2014
- Country
- SVM Canada
- STOK United States
- Employees
- SVM N/A
- STOK N/A
- Industry
- SVM Precious Metals
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- SVM Basic Materials
- STOK Health Care
- Exchange
- SVM Nasdaq
- STOK Nasdaq
- Market Cap
- SVM 1.4B
- STOK 1.3B
- IPO Year
- SVM N/A
- STOK 2019
- Fundamental
- Price
- SVM $7.00
- STOK $25.56
- Analyst Decision
- SVM Strong Buy
- STOK Strong Buy
- Analyst Count
- SVM 1
- STOK 6
- Target Price
- SVM $6.75
- STOK $26.60
- AVG Volume (30 Days)
- SVM 7.0M
- STOK 1.1M
- Earning Date
- SVM 11-06-2025
- STOK 11-04-2025
- Dividend Yield
- SVM 0.36%
- STOK N/A
- EPS Growth
- SVM N/A
- STOK N/A
- EPS
- SVM 0.25
- STOK 0.91
- Revenue
- SVM $308,064,000.00
- STOK $199,893,000.00
- Revenue This Year
- SVM $6.17
- STOK $416.54
- Revenue Next Year
- SVM $35.69
- STOK N/A
- P/E Ratio
- SVM $28.11
- STOK $28.15
- Revenue Growth
- SVM 35.50
- STOK 1218.82
- 52 Week Low
- SVM $2.87
- STOK $5.35
- 52 Week High
- SVM $7.26
- STOK $25.61
- Technical
- Relative Strength Index (RSI)
- SVM 82.54
- STOK 72.90
- Support Level
- SVM $6.28
- STOK $23.25
- Resistance Level
- SVM $6.76
- STOK $24.97
- Average True Range (ATR)
- SVM 0.35
- STOK 1.11
- MACD
- SVM 0.11
- STOK -0.05
- Stochastic Oscillator
- SVM 88.27
- STOK 98.66
About SVM Silvercorp Metals Inc.
Silvercorp Metals Inc is a mineral exploration company, engaged in the acquisition, exploration, development, and mining of mineral properties. The company's producing mines are located in China, and exploration and development projects are located in China and Ecuador. Its project portfolio comprises the El Domo copper-gold and the Condor gold project in Ecuador. In addition, it operates several silver-lead-zinc mines at the Ying Mining District in Henan Province, China, and the GC silver-lead-zinc mine in Guangdong Province, China. A majority of the company's revenue is generated through the sale of silver concentrates. Its reportable operating segments are the Ying Mining District and GC Mine in China, which derive maximum revenue, and the El Domo and Condor projects in Ecuador.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.